Clearside Biomedical to Present Research on Proprietary Retinal Therapeutics Platform at 2014 ARVO Meeting

May 02, 2014 07:30 AM Eastern Daylight Time
ARVO 2014
ALPHARETTA, Ga.--(BUSINESS WIRE)--Clearside Biomedical, Inc., a privately held ophthalmic company developing and commercializing targeted therapeutics for the treatment of sight-threatening diseases, today announced that research on its proprietary retinal therapeutics platform will be presented at the 2014 Annual Meeting of the Association for Research and Vision in Ophthalmology (ARVO), May 4-8, 2014, in Orlando, FL.

Six poster presentations will occur during the ARVO Annual Meeting, including:

Patel SR, Verhoeven RS, Burke B, Viaud K, Edelhauser HF. Safety and Tolerability of Drugs within the Suprachoroidal Space in Albino Rabbits.[4886-C0082. May 7, 11:00 a.m.-12:45 p.m., Exhibit/Poster Hall SA, Ocular Toxicity/Toxicology]

Noronha G, Edelhauser HF, Patel SR, Burke B, Verhoeven RS. Safety and Toxicokinetics of Suprachoroidal Space Injections of Triamcinolone Acetonide Suspension in Albino Rabbits. [4887-C0083. May 7, 11:00 a.m.-12:45 p.m., Exhibit/Poster Hall SA, Ocular Toxicity/Toxicology]

Yoo JI, Andino RV, Zarnitsyn V, Strudthoff K, Patel SR, Edelhauser HF. Ultrasound Biomicroscopy to Visualize Suprachoroidal Injections in Enucleated Human Eyes. [5253-C0049. May 7, 3:45-5:30 p.m., Exhibit/Poster Hall SA, Drug Delivery #2]

Zarnitsyn V, Patel SR, Verhoeven RS, Lawrence MS. Characterization of Sodium Fluorescein Administered into the Suprachoroidal Space of Nonhuman Primates Using a Microneedle. [5258-C0054. May 7, 3:45-5:30 p.m., Exhibit/Poster Hall SA, Drug Delivery #2]

Edelhauser HF, Verhoeven RS, Burke B, Struble CB, Patel SR. Intraocular Distribution and Targeting of Triamcinolone Acetonide Suspension Administered into the Suprachoroidal Space. [5259-C0055. May 7, 3:45-5:30 p.m., Exhibit/Poster Hall SA, Drug Delivery #2]

Andino R, Allen EV, Patel SR, Edelhauser HF, Yoo JI. Intraocular Pressure Changes Resulting from Suprachoroidal and Intravitreal Injections in Ex-Vivo Porcine Eyes. [5265. May 7, 3:45-5:30 p.m., Exhibit/Poster Hall SA, Drug Delivery #2]

About Clearside Biomedical, Inc.

Clearside Biomedical, Inc., headquartered in Alpharetta, GA, is a clinical-stage ophthalmic pharmaceutical company developing and planning to commercialize therapeutics targeting diseases of the back of the eye that can lead to blindness. We have developed a pipeline of ophthalmic drug candidates using our differentiated approach, which we believe can improve the efficacy and safety of those therapies. Clearside Biomedical was founded by an executive team with extensive development and revenue growth expertise. This team strives for better delivery and performance of its therapeutic agents to improve the standard of care for patients with choroidal and retinal diseases. Visit www.clearsidebio.com for more information.

Contacts
Clearside Biomedical, Inc.:
Charles Deignan, 678-270-4005
[email protected]
or
Media:
Tad Heitmann, 714-273-2937
thei[email protected]

 

Suggested Articles

J&J figures its partner Genmab owes a share of Darzalex Faspro royalties to Halozyme for its subcutaneous delivery tech. Genmab doesn't agree.

Bexson Biomedical and Stevanato Group teamed up to develop a ketamine pump that may help patients better manage pain at home.

Australia's University of New South Wales and Uka Tarsadia University in India will join forces to explore contact lenses for ocular drug delivery.